These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24559688)

  • 1. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
    Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
    Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.
    Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP
    Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
    Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
    Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
    Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
    Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
    Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
    Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
    Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
    Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
    Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
    Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
    Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Dinter L; Karitzky PC; Schulz A; Wurm AA; Mehnert MC; Sergon M; Tunger A; Lesche M; Wehner R; Müller A; Käubler T; Niessner H; Dahl A; Beissert S; Schmitz M; Meier F; Seliger B; Westphal D
    Int J Cancer; 2024 Mar; 154(6):1057-1072. PubMed ID: 38078628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.
    Delgado-Goni T; Miniotis MF; Wantuch S; Parkes HG; Marais R; Workman P; Leach MO; Beloueche-Babari M
    Mol Cancer Ther; 2016 Dec; 15(12):2987-2999. PubMed ID: 27765851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
    Roller DG; Capaldo B; Bekiranov S; Mackey AJ; Conaway MR; Petricoin EF; Gioeli D; Weber MJ
    Oncotarget; 2016 Jan; 7(3):2734-53. PubMed ID: 26673621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
    Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
    Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy sustains mitochondrial respiration and determines resistance to BRAF
    Díaz-Gago S; Vicente-Gutiérrez J; Ruiz-Rodríguez JM; Calafell J; Álvarez-Álvarez A; Lasa M; Chiloeches A; Baquero P
    Autophagy; 2024 Jun; 20(6):1383-1397. PubMed ID: 38436206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
    Girotti MR; Lopes F; Preece N; Niculescu-Duvaz D; Zambon A; Davies L; Whittaker S; Saturno G; Viros A; Pedersen M; Suijkerbuijk BM; Menard D; McLeary R; Johnson L; Fish L; Ejiama S; Sanchez-Laorden B; Hohloch J; Carragher N; Macleod K; Ashton G; Marusiak AA; Fusi A; Brognard J; Frame M; Lorigan P; Marais R; Springer C
    Cancer Cell; 2015 Jan; 27(1):85-96. PubMed ID: 25500121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.